6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 108_CD Notes_NNS to_TO the_DT Company_NN financial_JJ statements_NNS UK_NNP GAAP_NNP As_IN at_IN December_NNP 31_CD ,_, 2005_CD A_DT Presentation_NN of_IN the_DT financial_JJ statements_NNS Directors_NNS emoluments_NNS and_CC employees_NNS Details_NNS of_IN Directors_NNS remuneration_NN can_MD be_VB found_VBN in_IN Note_NN 37_CD and_CC the_DT Description_NN of_IN the_DT business_NN Directors_NNS Remuneration_NNP Report_NNP of_IN the_DT Group_NNP accounts_NNS ._.
There_EX was_VBD The_DT Company_NN was_VBD incorporated_VBN as_IN Trushelfco_NNP No._NN ._.
3167_CD Limited_JJ on_IN one_CD employee_NN of_IN the_DT Company_NN in_IN the_DT period_NN period_NN June_NNP 27_CD ,_, 2005_CD June_NNP 27_CD ,_, 2005_CD ._.
On_IN September_NNP 6_CD ,_, 2005_CD the_DT Company_NN was_VBD re-registered_VBN to_TO September_NNP 5_CD ,_, 2005_CD :_: no_DT employees_NNS ._.
as_IN a_DT public_JJ limited_JJ company_NN and_CC changed_VBD its_PRP$ name_NN to_TO Trushire_NNP plc._NN ._.
On_IN September_NNP 12_CD ,_, 2005_CD the_DT Company_NN changed_VBD its_PRP$ name_NN to_TO Shire_NNP plc._NN ._.
Details_NNS of_IN the_DT Groups_NNS share_NN option_NN schemes_NNS are_VBP contained_VBN in_IN the_DT Note_NN 31_CD of_IN the_DT Group_NNP accounts_NNS ._.
The_DT charge_NN recorded_VBN by_IN the_DT Company_NN during_IN Shire_NNP plc_NN is_VBZ the_DT parent_NN company_NN of_IN the_DT Shire_NNP Group_NNP ,_, the_DT principal_JJ activity_NN the_DT period_NN is_VBZ $_$ 76,000_CD period_NN from_IN June_NNP 27_CD ,_, 2005_CD to_TO September_NNP 5_CD ,_, 2005_CD :_: of_IN which_WDT is_VBZ the_DT research_NN ,_, development_NN and_CC marketing_NN of_IN prescription_NN $_$ nil_JJ relating_VBG to_TO one_CD director_NN ,_, being_VBG an_DT apportionment_NN of_IN the_DT group_NN medicines_NNS ._.
The_DT Group_NNP focuses_VBZ on_IN four_CD therapeutic_JJ areas_NNS :_: CNS_NNP ,_, GI_NNP ,_, charge_NN ._.
The_DT auditors_NNS remuneration_NN was_VBD $_$ 22,891_CD period_NN June_NNP 27_CD ,_, 2005_CD to_TO Preparation_NNP of_IN financial_JJ statements_NNS September_NNP 5_CD ,_, 2005_CD :_: nil_NN ._.
These_DT financial_JJ statements_NNS are_VBP drawn_VBN up_RP in_IN accordance_NN with_IN UK_NNP Generally_RB Accepted_JJ Accounting_NN Practice_NN UK_NNP GAAP_NNP as_IN at_IN December_NNP 31_CD ,_, 2005_CD ,_, with_IN comparative_JJ figures_NNS for_IN the_DT period_NN from_IN incorporation_NN B_NNP Accounting_NNP policies_NNS on_IN June_NNP 27_CD ,_, 2005_CD to_TO September_NNP 5_CD ,_, 2005_CD ._.
Intangible_JJ assets_NNS brand_NN name_NN As_IN permitted_VBN by_IN section_NN 230_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD ,_, the_DT profit_NN and_CC Intangible_JJ assets_NNS comprise_VBP the_DT cost_NN of_IN acquiring_VBG a_DT brand_NN name_NN ,_, which_WDT loss_NN account_NN of_IN the_DT Company_NN is_VBZ not_RB presented_VBN in_IN this_DT annual_JJ report_NN ._.
has_VBZ not_RB been_VBN amortised_VBN as_IN the_DT end_NN of_IN its_PRP$ useful_JJ economic_JJ life_NN can_MD not_RB The_DT Company_NN reported_VBD a_DT loss_NN for_IN the_DT period_NN from_IN September_NNP 5_CD ,_, 2005_CD be_VB foreseen_VBN ._.
Provision_NNP is_VBZ made_VBN for_IN any_DT impairment_NN ._.
Investments_NNP Investments_NNP held_VBD as_IN fixed_JJ assets_NNS are_VBP stated_VBN at_IN cost_NN or_CC ,_, if_IN applicable_JJ On_IN November_NNP 25_CD ,_, 2005_CD the_DT Company_NN became_VBD the_DT holding_VBG company_NN under_IN section_NN 131_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD ,_, the_DT nominal_JJ value_NN of_IN of_IN Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN SPG_NNP pursuant_JJ to_TO a_DT scheme_NN of_IN the_DT shares_NNS issued_VBN ,_, less_JJR any_DT provision_NN for_IN impairment_NN ._.
arrangement_NN under_IN section_NN 425_CD of_IN the_DT UK_NNP Companies_NNP Act_NNP 1985_CD that_WDT was_VBD approved_VBN by_IN the_DT High_NNP Court_NNP of_IN Justice_NNP in_IN England_NNP and_CC Wales_NNP and_CC Exchangeable_JJ shares_NNS the_DT shareholders_NNS of_IN SPG_NNP the_DT Scheme_NNP of_IN Arrangement_NNP ._.
Further_JJ details_NNS The_DT exchangeable_JJ shares_NNS are_VBP included_VBN as_IN part_NN of_IN share_NN capital_NN in_IN the_DT are_VBP in_IN Note_NN H._NNP Companys_NNP balance_NN sheet_NN to_TO present_VB a_DT true_JJ and_CC fair_JJ view_NN of_IN the_DT Companys_NNPS capital_NN structure_NN ,_, which_WDT differs_VBZ from_IN the_DT Companies_NNS Act_NNP As_IN a_DT consequence_NN of_IN the_DT Scheme_NN of_IN Arrangement_NN ,_, the_DT Companys_NNP 1985_CD requirements_NNS to_TO reflect_VB these_DT amounts_NNS as_IN minority_NN interests_NNS ,_, functional_JJ currency_NN and_CC presentational_JJ currency_NN is_VBZ now_RB the_DT US_NNP Dollar_NNP as_IN they_PRP will_MD become_VB ,_, and_CC are_VBP equivalent_JJ ,_, to_TO ordinary_JJ shares_NNS ._.
Comparatives_NNS have_VBP accordingly_RB been_VBN restated_VBN using_VBG the_DT exchange_NN rate_NN prevailing_VBG at_IN September_NNP 5_CD ,_, 2005_CD ._.
Dividends_NNS paid_VBD and_CC received_VBD Dividend_NN distribution_NN to_TO the_DT Companys_NNPS shareholders_NNS is_VBZ recognized_VBN as_IN Accounting_NNP convention_NN and_CC standards_NNS a_DT liability_NN in_IN the_DT Companys_NNPS financial_JJ statements_NNS in_IN the_DT period_NN in_IN which_WDT The_DT balance_NN sheet_NN has_VBZ been_VBN prepared_VBN under_IN the_DT historical_JJ cost_NN the_DT shareholders_NNS right_RB to_TO receive_VB payment_NN is_VBZ established_VBN ._.
This_DT occurs_VBZ convention_NN and_CC complies_NNS with_IN applicable_JJ UK_NNP accounting_NN standards_NNS ._.
in_IN the_DT period_NN in_IN which_WDT the_DT dividends_NNS are_VBP approved_VBN by_IN the_DT Companys_NNP shareholders_NNS ,_, or_CC in_IN the_DT case_NN of_IN an_DT interim_JJ dividend_NN ,_, when_WRB the_DT dividend_NN Accounting_NN principles_NNS and_CC policies_NNS is_VBZ paid_VBN ._.
The_DT preparation_NN of_IN the_DT balance_NN sheet_NN in_IN conformity_NN with_IN UK_NNP GAAP_NNP requires_VBZ management_NN to_TO make_VB estimates_NNS and_CC assumptions_NNS that_WDT Expenditure_NNP affect_VB the_DT reported_VBN amounts_NNS of_IN assets_NNS and_CC liabilities_NNS and_CC disclosure_NN Expenditure_NN is_VBZ recognized_VBN in_IN respect_NN of_IN goods_NNS and_CC services_NNS received_VBN of_IN contingent_JJ assets_NNS and_CC liabilities_NNS at_IN the_DT balance_NN sheet_NN date_NN ._.
Actual_JJ when_WRB supplied_VBN in_IN accordance_NN with_IN contractual_JJ terms_NNS ._.
Provision_NNP is_VBZ made_VBN amounts_NNS could_MD differ_VB from_IN those_DT estimates_NNS ._.
when_WRB an_DT obligation_NN exists_VBZ for_IN a_DT future_JJ liability_NN in_IN respect_NN of_IN a_DT past_JJ event_NN and_CC where_WRB the_DT amount_NN of_IN the_DT obligation_NN can_MD be_VB reliably_RB estimated_VBN ._.
The_DT balance_NN sheet_NN has_VBZ been_VBN prepared_VBN in_IN accordance_NN with_IN the_DT Companys_NNP accounting_NN policies_NNS approved_VBN by_IN the_DT Board_NNP and_CC described_VBN in_IN Note_NN B._NNP 108_CD Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN
